Validity of composite end points in clinical trials

被引：303

作者：

Montori, VM

Permanyer-Miralda, G ^{[1
]}

Ferreira-González, I

Busse, JW

Pacheco-Huergo, V

Bryant, D

Alonso, J

Akl, EA

Domingo-Salvany, A

Mills, E

Wu, P

Schünemann, HJ

Jaeschke, R

Guyatt, GH

机构：

[1] Hosp Gen Valle Hebron, Epidemiol Unit, Serv Cardiol, Barcelona 08035, Spain

[2] Mayo Clin, Coll Med, Dept Med, Rochester, MN 55905 USA

[3] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada

[4] McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada

[5] Inst Catala Salut, EAP Vilapicina, Primary Care Ctr Turo, Barcelona, Spain

[6] Inst Municipal Invest Med, Hlth Serv Res Unit, E-08003 Barcelona, Spain

[7] SUNY Buffalo, Dept Med & Social Prevent Med, Buffalo, NY 14214 USA

[8] Canadian Coll Naturopath Med, Dept Res, Toronto, ON M2K 1E2, Canada

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2005年 / 330卷 / 7491期

关键词：

D O I：

10.1136/bmj.330.7491.594

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Use of composite end points as the main outcome in randomised trials can hide wide differences in the individual measures. How should you apply the results to clinical practice?

引用

页码：594 / 596

页数：3

共 7 条

[1] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

[2] Composite outcomes in randomized trials - Greater precision but with greater uncertainty? [J].

Freemantle, N ;

Calvert, M ;

Wood, J ;

Eastaugh, J ;

Griffin, C .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (19) :2554-2559

[3] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [J].

Gent, M ;

Beaumont, D ;

Blanchard, J ;

Bousser, MG ;

Coffman, J ;

Easton, JD ;

Hampton, JR ;

Harker, LA ;

Janzon, L ;

Kusmierek, JJE ;

Panak, E ;

Roberts, RS ;

Shannon, JS ;

Sicurella, J ;

Tognoni, G ;

Topol, EJ ;

Verstraete, M ;

Warlow, C .

LANCET, 1996, 348 (9038) :1329-1339

[4] Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease [J].

Niewoehner, DE ;

Erbland, ML ;

Deupree, RH ;

Collins, D ;

Gross, NJ ;

Light, RW ;

Anderson, P ;

Morgan, MA .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (25) :1941-1947

[5]

Pfisterer M, 2001, LANCET, V358, P951

[6] Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial [J].

Taylor, DW ;

Barnett, HJM ;

Haynes, RB ;

Ferguson, GG ;

Sackett, DL ;

Thorpe, KE ;

Simard, D ;

Silver, FL ;

Hachinski, V ;

Clagett, GP ;

Barnes, R ;

Spence, JD .

LANCET, 1999, 353 (9171) :2179-2184

[7]

Yusuf S, 2000, NEW ENGL J MED, V342, P145

← 1 →